Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about January 24, 2023.
- Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about January 24, 2023.
- The Sesen Bio Board recommends that stockholders vote “FOR” each of the proposals listed on the WHITE proxy card enclosed with the definitive proxy statement / prospectus.
- In addition to the definitive proxy statement / prospectus, Sesen Bio has also mailed a letter to the Company’s stockholders.
- The Sesen Bio Board of Directors unanimously believes the pending merger with Carisma Therapeutics is the most value maximizing option available for Sesen Bio stockholders.